Announcements - OBI Pharma 台灣浩鼎

2023.Dec.01

OBI has filed the application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to US FDA

2023.Nov.10

OBI is invited to attend the investor conference hosted by MasterLink Securities and declare the development of all its products and future plan

2023.Nov.06

The change of the Company's business address was approved by the Board of Directors

2023.Nov.06

Announcement of change of internal audit officer

2023.Nov.06

Announcement of change of financial officer

2023.Nov.06

Announcement of the Consolidated Financial Statements for the third quarter of 2023 were approved by the Board of Directors

2023.Aug.07

Announcement on behalf of Amaran that the institutional director changes its representative

2023.Aug.07

The Company’s Board of Directors resolved to revise 2023 Employee Stock Option Issuance and Subscription Rules

2023.Aug.07

Announcement of the Consolidated Financial Statements for the second quarter of 2023 were approved by the Board of Directors

2023.Jul.03

OBI licensed “Nectin-4 Human Antibody” rights from Ablexis, LLC

News

Latest news

Events

Latest events